Sequential Docetaxel: No Benefit in Early Breast Cancer

MedPage Today -- WHEELING, W.Va., May 15 -- Adding docetaxel (Taxotere) to standard anthracycline-based adjuvant chemotherapy failed to improve five-year survival or recurrence of breast cancer in a large randomized trial, British researchers said.